Wisp’s menopause page places micronized progesterone, Provera and other oral options beneath one hormone heading. That shorthand may organize a service menu, but it should not organize the medicines into a false equivalence. The names refer to records that need to be read separately.
Reviewed September 29, 2026, this assessment uses Wisp’s public consultation and terms alongside exact manufacturer and official-label references. It does not assume that a reader will receive any particular listed option. No clinical assessment, selected pharmacy order, ingredient inspection or treatment response was tested.
Read this article by section
The category heading is broader than one active ingredient
Wisp’s consultation page lists micronized progesterone and Provera together with other oral options. The manufacturer’s Provera information identifies medroxyprogesterone acetate tablets. That is not the active-ingredient identity given in the Prometrium progesterone label.
The progesterone-versus-progestin guide explains why those names should not be treated as synonyms for a single product. Both can appear within a hormone-care service without having identical formulations or evidence. This distinction is not advice to prefer, replace or avoid one medicine; it is the minimum identification needed before a meaningful comparison of an actual prescription can begin. The distinction also prevents a price comparison from becoming misleading. Two medicines listed within the same appointment service should not be assumed to involve the same pharmacy charge, formulation or clinical reason for selection.
Micronized narrows the terminology without identifying the whole supply
The word micronized appears in Wisp’s published menu, but the entry does not name a manufacturer or provide the complete label for the eventual product. It also does not authenticate its ingredients or dispensing quantity. A more detailed clinical and pharmacy record is still necessary.
The micronized meaning discussion distinguishes that term from the name of a finished preparation. Alloy’s review considers another pill offer with approval and identity words close together. In neither case can the missing manufacturer and formulation be supplied by choosing the most familiar brand. A term describing the hormone does not independently verify a patient’s medicine.
Exact labels reveal differences that the service heading conceals
The Provera manufacturer record describes tablets containing medroxyprogesterone acetate and lists their own inactive ingredients. The Prometrium record instead describes oral micronized progesterone capsules and includes peanut oil and gelatin. These references identify their respective products, not a Wisp patient’s selected prescription.
A useful review does not move either ingredient list onto the entire oral-options menu. Personal ingredient concerns require identification of what will actually be dispensed and advice from the relevant professionals. Nor should different inactive ingredients be treated as a simple ranking of safety. This assessment makes no allergy determination and does not establish the formulation of an unnamed generic or another oral option.
Estrogen routes should not become progesterone routes by association
Wisp’s menu separately describes estrogen patches, gels and oral options. Their proximity to the progesterone heading is not evidence that the service offers every hormone by each route. The active medicine and form must stay connected when the offer is summarized.
The route guide explains why evidence cannot be transferred simply by changing an administration word. Stella’s review considers similar confusion within sample multi-part plans. Neither source authorizes use of an oral capsule through a different route. A clinician’s actual prescription, supported by the correct product information, is needed instead of a regimen assembled from neighboring website entries.
The advertised payment is for clinical access
The consultation offer starts at $33 per month, covering the consultation, follow-ups and monthly care-team access. Medicines, if prescribed, are paid for separately at the local pharmacy. The amount is therefore not a complete price for a specific micronized capsule or Provera supply.
The page advertises availability in all fifty states and same-day transmission of prescriptions when issued. Those statements do not establish individual eligibility, pharmacy stock or a guaranteed dispensing time. Its public FAQ headings do not provide all access answers in the reviewed record. A selected quote needs the medicine, quantity, pharmacy price and applicable clinical conditions rather than an assumption that every listed option shares one cost.
A recurring account does not dispense without a valid prescription
Wisp’s terms require a clinician to determine that a prescription product is appropriate and issue a valid prescription. Their subscription provisions also retain clinical review conditions. Continuing payment should not be mistaken for permission to obtain every item named on the menopause page.
To avoid the next periodic charge, the terms require cancellation at least forty-eight hours before the relevant renewal or refill period. Product sales are generally final, with possible remedies in the stated circumstances left to Wisp’s discretion. Those terms do not establish a separate local pharmacy’s refund policy or tell a patient how to alter clinical treatment when an account changes.
Approval and choice need the correct product record
FDA’s generic-drug explanation describes approval requirements for a generic corresponding to its reference product. It does not establish equivalence between progesterone and every progestin or between two unidentified preparations. The approval guide keeps regulatory status distinct from broad hormone terminology.
Wisp provides a documented route to discuss menopause treatment, with several named possibilities. The review’s conclusion is that those possibilities require separate identification and explanation. An accurate conversation would name the proposed active ingredient, form and product, establish its intended role and clarify the actual purchase. A shared website heading cannot perform that work or predict which option would be appropriate after assessment.
Documents behind the details
Read the source for the product, use and context it actually describes. A source type is not a rating of a provider.
- Wisp: menopause consultationDated provider offer naming micronized progesterone and other oral options; starting care charge excludes local-pharmacy medicine, eligibility FAQ extraction incomplete · Checked 2026-09-28
- Pfizer Medical: Provera medroxyprogesterone acetateManufacturer medicine information; active-drug/tablet identity to distinguish Provera from micronized progesterone capsules, no dosing or study-result transfer · Checked 2026-09-29
- DailyMed: Prometrium progesterone capsule label, updated July 23, 2026Official structured label for the named oral product; chemical identity, micronization, formulation-specific ingredients and indications, not evidence of a reviewed provider supplying it · Checked 2026-09-29
- Wisp: terms of useDated platform transaction terms; prescription renewal review, 48-hour cancellation and discretionary product remedies; not individual legal advice · Checked 2026-09-28
- FDA: Generic Drug FactsFederal generic-drug approval explanation; exact active ingredient, strength, dosage form, route and bioequivalence requirements, not a selected product or substitution instruction · Checked 2026-09-29